Baillie Gifford & Co. Sells 2,401,588 Shares of Tempus AI, Inc. $TEM

Baillie Gifford & Co. cut its position in Tempus AI, Inc. (NASDAQ:TEM) by 19.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,692,441 shares of the company’s stock after selling 2,401,588 shares during the quarter. Baillie Gifford & Co. owned about 5.58% of Tempus AI worth $782,277,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in TEM. Cranbrook Wealth Management LLC purchased a new stake in Tempus AI in the 3rd quarter worth about $25,000. Concord Wealth Partners boosted its position in Tempus AI by 308.0% during the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock worth $26,000 after purchasing an additional 308 shares during the period. GAMMA Investing LLC bought a new position in Tempus AI during the third quarter worth about $28,000. Allworth Financial LP increased its stake in shares of Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after purchasing an additional 450 shares in the last quarter. Finally, SouthState Corp raised its position in shares of Tempus AI by 3,761.5% in the second quarter. SouthState Corp now owns 502 shares of the company’s stock valued at $32,000 after purchasing an additional 489 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Performance

NASDAQ TEM opened at $65.32 on Friday. The company’s 50 day simple moving average is $68.87 and its two-hundred day simple moving average is $73.68. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. Tempus AI, Inc. has a 1 year low of $36.22 and a 1 year high of $104.32. The stock has a market capitalization of $11.62 billion, a PE ratio of -54.89 and a beta of 5.22.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. The firm had revenue of $334.21 million for the quarter, compared to analysts’ expectations of $328.89 million. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The business’s quarterly revenue was up 84.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.46) earnings per share. Analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Insider Transactions at Tempus AI

In other news, Director Jennifer A. Doudna sold 676 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $75.55, for a total transaction of $51,071.80. Following the completion of the transaction, the director owned 23,952 shares of the company’s stock, valued at approximately $1,809,573.60. The trade was a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Erik Phelps sold 1,302 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $67.42, for a total transaction of $87,780.84. Following the completion of the sale, the executive vice president directly owned 89,280 shares in the company, valued at $6,019,257.60. This represents a 1.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 932,832 shares of company stock worth $71,184,024. 26.27% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TEM has been the topic of a number of recent research reports. Guggenheim upped their price target on shares of Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, September 26th. Morgan Stanley boosted their target price on shares of Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, December 1st. HC Wainwright cut their price target on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a report on Friday, November 7th. TD Cowen cut Tempus AI from a “buy” rating to a “hold” rating in a research report on Tuesday, October 21st. Finally, Needham & Company LLC boosted their price objective on Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $87.20.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.